Ep. 193 Bladder Cancer Innovations: ESMO 2024 Highlights with Dr. Andrea Apolo

1889.254 - 1914.331 Dr. Andrea Apolo

So so we categorize patients into high risk and low risk patients. Right. And yes, the high risk patients had CT DNA, but not all of them did. And then there were some patients that were not high risk, you know, by our criteria. And they about half of them still had positive CT DNA. So, you know, we think we're good using clinical baseline characteristics in terms of how to make patient how to.